Rho Kinase Inhibitors: Potential Treatments for Diabetes and Diabetic Complications

Author(s): Hong Zhou, Yong-jun Li

Journal Name: Current Pharmaceutical Design

Volume 18 , Issue 20 , 2012

Become EABM
Become Reviewer
Call for Editor


The small GTPase RhoA and its downstream effector, Rho kinase (ROCK), appear to mediate numerous pathophysiological signals, including smooth muscle cell contraction, actin cytoskeleton organization, cell adhesion and motility, proliferation, differentiation and the expression of several genes. Clinical interest in the RhoA/ROCK pathway has increased, due to emerging evidence that this signaling pathway is involved in the pathogenesis of several diseases, including hypertension, coronary vasospasm, stroke, atherosclerosis, heart failure and diabetes; ROCK is considered an important future therapeutic target. Several pharmaceutical companies are already actively engaged in the development of ROCK inhibitors as the next generation of therapeutic agents for these diseases. This review discusses the relationship between diabetes and hyperglycemia-induced RhoA/ROCK activation, highlights recent findings on the roles of ROCK inhibitors from experimental models of diabetes and clinical studies in cardiovascular patients, and elucidates major challenges for developing more selective ROCK inhibitors. Accumulating evidence suggests the potential of ROCK inhibitors as therapeutic agents for diabetes and its complications.

Keywords: RhoA, Rho kinase, inhibitors, diabetes, complications, GTPase, hypertension, coronary vasospasm, stroke, atherosclerosis

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Page: [2964 - 2973]
Pages: 10
DOI: 10.2174/138161212800672688
Price: $65

Article Metrics

PDF: 42